Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion type Assertion NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_head.
- NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion description "[Taken together with similar recent studies of neuroblastoma- and glioblastoma-derived cells, PI3K inhibition seems to be a more general option to sensitize tumor cells to anthracyclines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_provenance.
- NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion evidence source_evidence_literature NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_provenance.
- NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion SIO_000772 23300809 NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_provenance.
- NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion wasDerivedFrom befree-20140225 NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_provenance.
- NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_assertion wasGeneratedBy ECO_0000203 NP440939.RAy584VPcnlEv4Zc_GZn6TRgZ6G0uR3KCbQkth7ZqiAts130_provenance.